



Atty. Dkt. No. 034536-1481

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Axel ULLRICH et al.

Title: NOVEL PTP-20, PCP-2, BDP1, CLK, AND SIRP PROTEINS AND
RELATED PRODUCTS AND METHODS

Appl. No.: 10/087,993

Filing Date: 03/05/2002

Examiner: Hope Robinson

Art Unit: 1653

**STATEMENT TO SUPPORT FILING AND SUBMISSION IN
ACCORDANCE WITH 37 CFR 1.821-1.825**

Mail Stop Missing Parts
Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

In connection with a Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

1. the submission, filed herewith in accordance with 37 C.F.R. § 1.821(g), does not include new matter;

2. the content of the attached paper copy and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same.

Date 2 August 2004

FOLEY & LARDNER LLP

Customer Number: 22428

Telephone: (202) 672-5475

Facsimile: (202) 672-5399

Respectfully submitted,

By

Beth A. Burrous

Attorney for Applicants

Registration No. 35,087



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Axel ULLRICH et al.

Title: Novel PTP-20, PCP-2, BDP1, CLK, And SIRP Proteins And
Related Products And Methods

Appl. No.: 10/087,993

Filing Date: March 5, 2002

Examiner: Hope Robinson

Art Unit: 1653

RESPONSE TO OFFICE COMMUNICATION DATED JULY 2, 2004,
AND
NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES UNDER 37 C.F.R. § 1.821-1.825

Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450
Box SEQUENCE

Sir:


This paper is filed in response to the Office Communication dated July 2, 2004, and the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures Under 37 C.F.R. § 1.821-1.825 mailed July 2, 2004. This Response is timely, as it is filed within the stated one-month period.

The Notice to Comply requires (A) "An initial or substitute computer readable form (CRF) of the 'Sequence Listing'", (B) "An initial or substitute paper copy or compact disc of the 'Sequence Listing,' as well as an amendment directing its entry into the specification", (C) "A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required under 37 C.F.R. § 1.821(e) or 1.821(f) or 1.821(g)", and (D) a copy of the Notice to Comply. Each item (A-D) is believed fully responded to by this filing.

Specifically, item (A) is believed satisfied by the submission of one (1) computer readable disc of the Sequence Listing, which is believed to comply with 37 C.F.R. §§ 1.821-825. Additionally, item (B) is believed satisfied by the Amendment and Reply to Office Communication dated July 2, 2004, filed with this paper. Lastly, as noted in item (C), the Statement to Support Filing and Submission in Accordance with 37 CFR §§ 1.821-1.825, filed with this paper, the Sequence Listing of the computer readable copy is the same as the paper-readable copy, and the sequence submission does not include new matter.

As a result, it is respectfully submitted that the present response to the Office Communication and Notification, dated July 2, 2004, is complete. If there are any questions, please contact the undersigned attorney.

Respectfully submitted,

By 

Date August 2, 2004

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5475
Facsimile: (202) 672-5399

Beth A. Burrous
Attorney for Applicant
Registration No. 35,087

Should additional fees be necessary in connection with the filing of this paper, or if a petition for extension of time is required for timely acceptance of same, the Commissioner is hereby authorized to charge Deposit Account No. 19-0741 for any such fees; and applicant(s) hereby petition for any needed extension of time.